Reply to letters on review ‘Evolving treatment strategies for myeloma’

por Morgan, G J, Davies, F E
Publicado 2005

Evolving treatment strategies for myeloma

por Morgan, G J, Davies, F E
Publicado 2005

Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia

por Moorman, A V, Roman, E, Cartwright, R A, Morgan, G J
Publicado 2002

Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups

por Moorman, A V, Roman, E, Cartwright, R A, Morgan, G J
Publicado 2002

Three-dimensional image fusion guidance of percutaneous pulmonary valve implantation to reduce radiation exposure and contrast dose: A comparison with traditional two-dimensional a...

por Goreczny, S., Moszura, T., Dryzek, P., Lukaszewski, M., Krawczuk, A., Moll, J., Morgan, G. J.
Publicado 2016

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical applica...

por Aronson, L I, Davenport, E L, Mirabella, F, Morgan, G J, Davies, F E
Publicado 2013

Fluorescent polymerase chain reaction of a panel of CA repeats on chromosome 6 in the indolent phase of follicular centre cell lymphoma.

por Randerson, J., Cawkwell, L., Jack, A., Lewis, F., Johnson, P., Evans, P., Barrans, S., Morgan, G. J.
Publicado 1996

Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms

por Willett, E V, Skibola, C F, Adamson, P, Skibola, D R, Morgan, G J, Smith, M T, Roman, E
Publicado 2005

MMSET is the key molecular target in t(4;14) myeloma

por Mirabella, F, Wu, P, Wardell, C P, Kaiser, M F, Walker, B A, Johnson, D C, Morgan, G J
Publicado 2013

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado 2018

Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease bur...

por Giles, S.L., deSouza, N.M., Collins, D.J., Morgan, V.A., West, S., Davies, F.E., Morgan, G.J., Messiou, C.
Publicado 2015

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

por Pawlyn, C, Fowkes, L, Otero, S, Jones, J R, Boyd, K D, Davies, F E, Morgan, G J, Collins, D J, Sharma, B, Riddell, A, Kaiser, M F, Messiou, C
Publicado 2016

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

por Walker, B A, Wardell, C P, Brioli, A, Boyle, E, Kaiser, M F, Begum, D B, Dahir, N B, Johnson, D C, Ross, F M, Davies, F E, Morgan, G J
Publicado 2014

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

por Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S
Publicado 2014

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

por Jones, J. R., Barber, A., Le Bihan, Y-V, Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M. F., Jackson, G. H., Davies, F. E., Chopra, R., Morgan, G. J., Pawlyn, C.
Publicado 2021

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

por Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Publicado 2017

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

por Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., Buzder, T., Molnar, G., Zangari, M., van Rhee, F., Thanendrarajan, S., Schinke, C., Epstein, J., Davies, F. E., Walker, B. A., Meissner, T., Barlogie, B., Morgan, G. J., Weinhold, N.
Publicado 2017

Genetic factors influencing the risk of multiple myeloma bone disease

por Johnson, D C, Weinhold, N, Mitchell, J, Chen, B, Stephens, O W, Försti, A, Nickel, J, Kaiser, M, Gregory, W A, Cairns, D, Jackson, G H, Hoffmann, P, Noethen, M M, Hillengass, J, Bertsch, U, Barlogie, B, Davis, F E, Hemminki, K, Goldschmidt, H, Houlston, R S, Morgan, G J
Publicado 2016

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

por Jones, J R, Cairns, D A, Gregory, W M, Collett, C, Pawlyn, C, Sigsworth, R, Striha, A, Henderson, R, Kaiser, M F, Jenner, M, Cook, G, Russell, N H, Williams, C, Pratt, G, Kishore, B, Lindsay, J, Drayson, M T, Davies, F E, Boyd, K D, Owen, R G, Jackson, G H, Morgan, G J
Publicado 2016